Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07654972

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 30 to 39 weeks (7 to 10 months).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lilly Centre for Clinical Pharmacology, Singapore

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
  • Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
  • Have had a self-reported stable weight for 3 months prior to screening

Exclusion criteria

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
  • Is an individual of childbearing potential (IOCBP)

Treatment and study plan

LY4174794

Drug

Administered SC.

Placebo

Drug

Administered SC.

Primary outcomes

  1. Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through end of the Follow-up (Week 25)

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.

  2. Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through end of the Follow-up (Week 33)

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.

Secondary outcomes

  1. Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)

  2. Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)

  3. Part B: PK: Maximum Observed Drug Concentration (Cmax) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)

  4. Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)

Study contacts

Contact information is provided by the study sponsor or research team.

Physicians interested in becoming principal investigators please contact

CONTACT

[email protected]

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

[email protected]

1-317-615-4559

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 17, 2026
Registry last updated
Sep 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.